Unlearn.AI adds Mira Murati to its Board of Directors

– USA, CA –  Unlearn, a pioneering technology company using AI-generated digital twins of individual patients to revolutionize medical research, today announced the appointment of Mira Murati to its Board of Directors.

“I’m incredibly excited to have Mira join the Unlearn team. Unlearn’s founding team worked with Mira at Leap Motion, so it feels a bit like we’re putting the band back together. I don’t think anyone has more expertise than Mira in building and shipping AI-based products, and I know she’ll help us drive towards our goal of being the most innovative AI company in healthcare,” said Founder and CEO, Dr. Charles Fisher.

About Mira Murati

As CTO of OpenAI, Ms. Murati leads research and product development teams for groundbreaking applications including DALL-E and ChatGPT. She brings over a decade of leadership experience at trailblazing tech companies, including managing the product and engineering teams at Ultraleap and leading the design, development, and launch of vehicle products such as the Model X at Tesla Motors.

“Unlearn is pioneering both research and deployment of generative AI technologies for healthcare, used today to run more efficient clinical trials and with massive potential for the future of precision medicine,” said Mira Murati. “As someone who is deeply invested in how AI will benefit humanity, I’m excited to help the Unlearn team pursue their vision to advance AI to eliminate trial and error in medicine.”

About Unlearn.ai

Unlearn is a San Francisco-based technology company pioneering AI-generated digital twins that forecast health outcomes for individual patients. Founded in 2017, Unlearn brings together a team of world-class innovators at the intersection of artificial intelligence, clinical, and regulatory science to transform the future of medicine through generative AI. Unlearn’s technology is regulatory-qualified and used by leading global pharmaceutical companies to run AI-powered clinical trials that reach full enrollment faster and bring new treatments to patients sooner.

For more information: https://www.unlearn.ai/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.